Medscape

FDA Approves Human Fibrinogen Concentrate for Treatment of Bleeding in Congenital Fibrinogen Deficiency

January 28, 2009 — On January 16, the US Food and Drug Administration (FDA) granted accelerated approval to human fibrinogen concentrate (RiaSTAP, CSL Behring). This orphan drug is intended for use in ...

FDA Approves New 2-Gram Presentation of Fibryga(R), Enhancing Convenience and Precision in Treating Acquired Fibrinogen Deficiency

Fibryga (R) is now approved in the U.S. for fibrinogen supplementation in both congenital and acquired fibrinogen deficiency, and is available in 1-gram and 2-gram kits, each with the nextaro (R) ...
News Medical

Fibrinogen a key player in health and disease, says new study

A new study from the University of Alberta demonstrated that the blood clotting protein called fibrinogen also regulates MMP-2, an enzyme involved in immunity and in clot formation inside blood ...
EurekAlert!

Understanding the impact of fibrinogen modifications on blood clot formation and degradation

The top panel, designed with BioRender.com, illustrates the process of clot formation and lysis, beginning with platelet aggregation and activation of the coagulation cascade, followed by the ...
Pharm Exec

FDA Approves Expanded Indication for Octapharma’s Fibryga for Patients Experiencing Bleeding Due to Acquired Fibrinogen Deficiency

Expanded indication makes Fibryga the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication. The FDA has approved an expanded indication ...
Nature

Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis

Activation of the immune system has been increasingly recognised to be associated with procoagulatory status in patients with inflammatory rheumatic disease. Changes in endothelial cell and platelet ...